Figure 3. Genomics alterations detected in patients presented at MTB. (a): Genomic alteration with potential benefit in patient’s tumour type. (b): Genomic alterations with potential therapeutical benefit in other tumour types. (c): Genomic alterations with no therapeutic benefit or resistance to treatment.